IMMUNITYBIO, INC. (IBRX) Free cash flow 2016–2025
IMMUNITYBIO, INC. (IBRX) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$308.8MFY2025 · since FY2016: -$45.2M → -$308.8M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$308.8M | +22.4% |
| FY2024 | -$398.1M | -0.2% |
| FY2023 | -$397.3M | +4.4% |
| FY2022 | -$415.7M | -35.0% |
| FY2021 | -$308.0M | -77.6% |
| FY2020 | -$173.4M | -10.9% |
| FY2019 | -$156.4M | -104.5% |
| FY2018 | -$76.5M | +8.5% |
| FY2017 | -$83.6M | -85.1% |
| FY2016 | -$45.2M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More IBRX financial trends
IBRX RevenueIBRX Net incomeIBRX Net marginIBRX Gross profitIBRX Gross marginIBRX Operating incomeIBRX Operating marginIBRX Operating cash flowIBRX Capital expendituresIBRX Return on equityIBRX Stock buybacksIBRX Dividends paidIBRX Total assetsIBRX Total liabilitiesIBRX Shareholders’ equityIBRX overview →